doi: 10.1016/s0140-6736(86)90367-3.
Protective efficacy of BCG against leprosy in Northern Malawi
- PMID: 2875247
- DOI: 10.1016/s0140-6736(86)90367-3
Item in Clipboard
Protective efficacy of BCG against leprosy in Northern Malawi
Lancet.
.
Abstract
The effectiveness of a BCG vaccination programme in protecting against leprosy was assessed by case-control and cohort analyses of data from the Lepra Evaluation Project in Karonga District, Northern Malawi. Results indicate that BCG provides at least 50% protection against leprosy in this population and that protection is independent of age, sex, schooling status, or location within the project area. Agreement between these findings and those from a controlled trial in Uganda indicates that BCG is sufficiently effective against leprosy in East and Central Africa to be considered an important element of leprosy control in that region.
Similar articles
-
Efficacy of BCG vaccine against leprosy and tuberculosis in northern Malawi.Lancet. 1992 Mar 14;339(8794):636-9. doi: 10.1016/0140-6736(92)90794-4. Lancet. 1992. PMID: 1347338
-
Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Karonga Prevention Trial Group.Lancet. 1996 Jul 6;348(9019):17-24. Lancet. 1996. PMID: 8691924 Clinical Trial.
-
Incidence rates of leprosy in Karonga District, northern Malawi: patterns by age, sex, BCG status and classification.Int J Lepr Other Mycobact Dis. 1994 Mar;62(1):10-23. Int J Lepr Other Mycobact Dis. 1994. PMID: 8189075
-
BCG vaccination in mycobacterial infections.Br Med Bull. 1969 May;25(2):183-8. doi: 10.1093/oxfordjournals.bmb.a070690. Br Med Bull. 1969. PMID: 4248333 Review. No abstract available.
-
Protecting people against leprosy: chemoprophylaxis and immunoprophylaxis.Clin Dermatol. 2015 Jan-Feb;33(1):19-25. doi: 10.1016/j.clindermatol.2014.07.009. Clin Dermatol. 2015. PMID: 25432807 Review.
Cited by
-
T-cell-mediated cytotoxicity against Mycobacterium antigen-pulsed autologous macrophages in leprosy patients.Infect Immun. 1992 Aug;60(8):3389-95. doi: 10.1128/iai.60.8.3389-3395.1992. Infect Immun. 1992. PMID: 1639507 Free PMC article.
-
Evidence that the Mitsuda reaction to Mycobacterium leprae can be mediated by lymphocytes responsive to Mycobacterium tuberculosis.Clin Exp Immunol. 1988 Jun;72(3):390-3. Clin Exp Immunol. 1988. PMID: 2458870 Free PMC article.
-
Immune profiling of leprosy and tuberculosis patients to 15-mer peptides of Mycobacterium leprae and M. tuberculosis GroES in a BCG vaccinated area: implications for development of vaccine and diagnostic reagents.Immunology. 2004 Apr;111(4):462-71. doi: 10.1111/j.0019-2805.2004.01839.x. Immunology. 2004. PMID: 15056384 Free PMC article.
-
Epidemiology of Tuberculosis in Malawi.Malawi Med J. 2006 Sep;18(3):147-59. Malawi Med J. 2006. PMID: 27529008 Free PMC article. No abstract available.
-
Bacillus of Calmette and Guérin (BCG) and the risk of leprosy in Ciudad del Este, Paraguay, 2016-2017.Epidemiol Health. 2021;43:e2021060. doi: 10.4178/epih.e2021060. Epub 2021 Sep 8. Epidemiol Health. 2021. PMID: 34525502 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
